Table 6.

Mean stiffness values (kPa) of FLLs measured by 2D-SWE with the associated cut-off values to differentiate malignant FLLs from benign FLLs.

Study	Cut-Off Value Malignant Versus Benign	Se/Sp (%)	HCC	Metastases	Hemangiomas	FNH	Hepatocellular Adenoma	Statistically Significant/Not Significant Difference between Stiffness of HCC and Other FLLs
Tian et al.1 [166]	39.60	87.74/83.67	61.83 ± 28.87 (n = 103)/Parenchyma: 15.94 ± 7.37	90.32 ± 54.71 (n = 35)/Parenchyma: 10.93 ± 36.64	20.56 ± 10.74 (n = 37)/Parenchyma: 9.04 ± 2.44	38.72 ± 18.65(n = 15)/Parenchyma: 9.09 ± 2.64	N/S	Significant difference: Intrahepatic cholangiocarcinomas—HCC (p < 0.0001) Significant difference: metastases—HCC (p = 0.0237) Significant difference: malignant—benign lesions (p < 0.001) Significant difference: HCC—FNHs (HCC > FNH, p = 0.0012)
Guibal et al. [167]	N/S	N/S	14.86 ± 10 (n = 26)	28.8 ± 16 (n = 53)	13.8 ± 5.5 (n = 22)	33 ± 14.7 (n = 16)	9.4 ± 4.3 (n = 10)	Significant difference: HCC—cholangiocarcinomas (p = 0.0004) Significant difference: HCC—metastases (p = 0.0059)
Wang et al. [168]	25.76 (Emean), 0.85 (combined score)	92.59/87.50 (combined score)	39.31 ± 12.50 (n = 83)	56.99 ± 33.13 (n = 24)	13.71 ± 9.24 (n = 33)	30.56 ± 11.86 (n = 11)	N/S	N/S
Ronot et al. [164]	N/S	N/S	19.6 (n = 1)	N/S	17.1 ± 7 (n = 20)	33.3 ± 12.7 (n = 60)	19.7 ± 9.8 (n = 17)	No significant difference: Malignant—benign lesions (p = 0.64)
Grgurevic et al. [169]	22.3	83/86	29.57 ± 11.67 (n = 57)	37.93 ± 10.61 (n = 94)	14.10 ± 6.44 (n = 71)	30.51 ± 32.05 (n = 20)	N/S	Significant difference: Malignant—benign lesions (p < 0.001)
Gerber et al. [170]	20.7	79.7/62	44.8 (range 15.8–97) (n = 16)	29.5 (range 4.1–142.9) (n = 41)	16.35 (range 5.4–71.9) (n = 18)	16.55 (range 2.1–69.7) (n = 18)	8.9 (n = 1)	Significant difference: Malignant—benign lesions (p < 0.0001) Significant difference: Cholangiocarcinomas—HCC (p = 0.033) Significant difference: Cholangiocarcinomas—metastases (p = 0.0079)

¹ only maximal stiffness values presented within the paper.